Applied Dna Sciences INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
BNB PLUS CORP. Director Joseph D. Ceccoli was granted 77,038 incentive stock options with an exercise price of $0.69, vesting over time.
BNB Plus Corp. Director and 10% owner James Haft was granted 77,038 non-qualified stock options with an exercise price of $0.69, vesting over one year.
BNB PLUS CORP. Director James Haft acquired 93,000 stock options with a $1.31 exercise price, vesting over four installments through February 2027.
BNB PLUS CORP. CEO Clay Shorrock was granted 84,388 stock options, comprising incentive and non-qualified options, with an exercise price of $2.52 per share.
BNB PLUS Corp.'s Chief Financial Officer, Beth Jantzen, was granted 84,388 stock options with an exercise price of $2.52, vesting quarterly.
Applied DNA Sciences CEO Clay Shorrock acquired 18,691 shares of common stock through a restricted stock unit grant, vesting in 90 days.
Applied DNA Sciences Director Joseph D. Ceccoli was granted 22,511 restricted stock units, increasing his beneficial ownership to 22,512 shares.
Applied DNA Sciences Director Robert Catell acquired 22,511 shares of common stock through a restricted stock unit grant.
Applied DNA Sciences' CFO, Beth Jantzen, acquired 18,691 shares of common stock as restricted stock units, vesting 90 days from the grant date.
Applied DNA Sciences director Elizabeth M. Schmalz was granted 22,511 shares of common stock, vesting in 90 days.
APPLIED DNA SCIENCES INC Director Yacov Shamash acquired 22,511 shares of common stock through a restricted stock unit grant.
APPLIED DNA SCIENCES Director Judith Murrah acquired 18,691 shares of common stock on October 17, 2025, increasing her beneficial ownership to 18,694 shares.